Group 1 - The company is guiding for 3.5% organic constant currency growth this year, following a 6% growth in 2025, indicating a diverse portfolio will drive this growth [1] - Core therapeutic areas include dermatology, parasitology, and pain management, with expectations for pain to return to growth in 2026, while parasitology is anticipated to lead growth this year due to increased competition in dermatology [2] - The diagnostics segment is performing well, and the livestock sector is highlighted as a bright spot, historically growing at 2% to 4% [3]

a first on CNBC interview is Elanco CEO Jeff Simmons. Jeff, I just want to talk about this because I have a personal interest as an owner of two dogs. And I want to say now, six fish.At this point, we have animals throughout our house. Our kids love them. What exactly is driving the demand for animal health products.To the point that we've seen your stock jump the way that it did. >> Tom, great to be with you this morning. And it's exactly that.And that is that the personalization of that pet in the home, t ...